Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

To join this study, you need to be at least 70 years old and have been diagnosed with advanced kidney cancer that has spread. This treatment should be the first you've received for your advanced cancer. You also need to be able to carry out most of your daily activities with little to no difficulty.

There are also some conditions that would mean you couldn't take part. For example, if you've recently been in another study testing a new drug, or if you have certain serious heart problems or blood clots in the last three months. Some existing health conditions that might react badly with the study drugs, such as untreated brain tumours or active auto-immune diseases that need strong medication, would also prevent you from joining. However, manageable thyroid or adrenal conditions are usually okay.

It's important that you understand and agree to participate by signing a consent form. You must also be covered by a social security system and be willing and able to attend all necessary appointments.

If you decide to take part, you will receive two medications: nivolumab and cabozantinib, as standard treatment. Before starting, you will have a detailed health assessment, including a special check-up focused on your overall health as an older adult. Throughout the study, you will have regular check-ups with your cancer doctor, and also with a nurse or doctor from a team that specialises in older people's health. This might involve phone calls between your clinic visits. For some patients, there might also be an optional extra check to see how the cabozantinib medicine is working in their body. The total duration of your participation will depend on how you respond to the treatment, but you will be closely monitored throughout.